Beauty brand ad creative compliance: the drug line, the MoCRA dates, and what Meta permits

You have a serum, a claim the founder loves, and a media buyer asking whether the before-and-after will get the account restricted. Most of the answers in circulation are folklore, repeated by people who have not opened the page this year. I opened them on September 3, 2026. What follows is a practitioner's reading of the public text rather than legal advice, and the line it turns on lives on FDA's page on whether a product is a cosmetic, a drug, or both.

01Which sentence turns a cosmetic into a drug?

The one that promises an effect on a disease, or on the structure or function of the body. FDA's definitions are short and old. A cosmetic cleanses, beautifies, promotes attractiveness or alters the appearance. A drug diagnoses, cures, mitigates, treats or prevents disease, or affects the structure or any function of the body. The copy picks the category and the product follows it there.

One FDA sentence settles the argument I have most often on briefing calls, about the industry's favorite word: "The term 'cosmeceutical' has no meaning under the law." And because FDA cannot clear a claim before a product ships, you will see cosmetics on sale making claims that go past what the law allows. A competitor's live ad is not precedent for yours.

There is no list of approved cosmetic claims to check yours against. There is only what the copy says the product does.

What I tell a beauty client on the first call

02MoCRA's dates have all passed

All four of them. Facility registration and product listing were due December 29, 2023, and FDA's own compliance policy said it would not enforce either until July 1, 2024. The label duty landed a year later: since December 29, 2024 a cosmetic label has had to carry a domestic address, a domestic phone number or electronic contact information through which the responsible person can receive adverse event reports.

The small-business exemption is where brands get comfortable too early. It covers registration, listing and good manufacturing practice for a brand averaging under $1,000,000 in annual US cosmetic sales across the previous three years. It never covered adverse event reporting, and it never covered safety substantiation. It also disappears at any revenue for four categories, among them products that contact the eye's mucous membrane in normal use. A brand doing $600,000 in liquid eyeliner is not exempt.

03Can you run before-and-after photos in a beauty ad?

On Meta, yes, for general cosmetic products, aimed at adults. I read the Health and Wellness standard on September 3, 2026. It lists "General cosmetic products, procedures, surgeries depicting before and after transformation" among the things an advertiser can run when targeting people 18 or older, and it says the ad can show people using the product and its impact, with the time taken to see results indicated. I could not find a current Meta standard banning the imagery anywhere on that page.

The rejections I have seen land on a different rule. Meta's personal attributes standard bars an ad that asserts or implies personal attributes, or that implies the advertiser knows them, and Meta's own worked pair carries the lesson: "Our new lotion and creams fight wrinkles like never before" is allowed, and "Ready to upgrade your skin to look younger?" is not. Describe the product. Do not address the reader's body. It costs one rewrite, the cheapest fix in this piece, and the platform-by-platform version sits in what each platform asks a US advertiser to disclose.

TikTok is stricter, and the difference has nothing to do with pictures. Its Weight Management and Body Image policy bars claims that looking a certain way makes a person more desirable, successful, happy or popular, and claims that body appearance determines confidence, self-esteem, desirability or social standing. So a beauty ad there pays off with the product and not with the better life behind it. That is a story decision, made on paper, weeks before anyone books a shoot.

04What the FTC wants behind the claim

Evidence qualified experts would accept, which for a health benefit claim usually means a trial. FTC's Health Products Compliance Guidance, published December 20, 2022, puts it in one sentence: "Randomized, controlled human clinical trials (RCTs) are the most reliable form of evidence and are generally the type of substantiation that experts would require for health benefit claims."

Two of the guidance's worked examples are about pictures, so they belong in a shot list rather than a legal file. In Example 6 an ad for a topical ointment shows an elderly woman with a walker, then dancing, and FTC reads the pair as a claim that the product dramatically improves arthritis symptoms. Nobody wrote that claim. In Example 41 a weight loss ad runs before-and-after photographs and fine print reading "These results are not typical," and FTC's verdict is that such disclaimers "don't cure the deception."

The Endorsement Guides add the line a review wall keeps walking into: "Consumer endorsements themselves are not competent and reliable scientific evidence." A testimonial delivered by a person who does not exist is a separate problem again, under the FTC rule at 16 CFR Part 465, priced per violation and taken apart in full here.

CLAIM BLOCK

Hero line, verbatim:      ______________________________
Category test:           appearance / structure or function
If structure or function -> stop, ask counsel, do not board it

Result shown or stated?  yes / no
If yes, typical result:  ______________________________
  and it prints:         adjacent to the claim, prominent type

Address:                 about the product / about the viewer
Payoff:                  the product / the life after it
Age targeting:           18+ where the platform requires it

Surfaces legible in frame (pack, carton, applicator, device):
  1. ____________________  claim? yes / no / ask counsel
  2. ____________________  claim? yes / no / ask counsel

Approved by: __________________   Date: __________

05The words printed on the product are in the ad

I shot a beauty device for a client. It prints mode names down the handle in small white type on gloss black, and in a macro frame EYE CARE and IMPORT come up at reading size. Nobody wrote those words into a script. FDA's intended-use test does not care who wrote them, since it counts claims stated on the product labeling, in advertising and in other promotional materials. Whether a mode name is a claim the brand can carry belongs to the brand and its counsel. Knowing which of those words a viewer can read is my job, and it belongs on the direction board rather than in the edit.

So a pack shot gets a copy review, the same as the voiceover: legible surface text, the back panel if the carton turns, molded lettering on an applicator. Beauty makes this worse than other categories, because the house style is macro coverage, and macro is where small print becomes headline type. Why every beauty ad already looks like every other beauty ad is the craft version of that trap, and a hand holding a product is where generated coverage is still hardest to get right.

Finding any of this out after the shoot costs the batch rather than the line, and what ad creative costs in the US makes that arithmetic plain before a first brief goes out. The frame almost never fails. A sentence fails, written in ten seconds three weeks earlier and never read again, and the frame goes down with it.